Coagulation Disorders and Bleeding Risks With Cefoperazone-Sulbactam
Of patients who received cefoperazone-sulbactam, 9.2% reported a coagulation disorder and 15.7% reported a decrease in platelet count.
Vicki Moore, PhD
Contributing Writer https://www.infectiousdiseaseadvisor.com
Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913
